{"id":"NCT04844918","sponsor":"Eli Lilly and Company","briefTitle":"A Study of Tirzepatide (LY3298176) in Participants With Obesity Disease","officialTitle":"Efficacy and Safety of Once-Weekly Tirzepatide in Participants With Obesity Disease: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-J)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-05-10","primaryCompletion":"2023-06-24","completion":"2023-06-24","firstPosted":"2021-04-14","resultsPosted":"2024-07-16","lastUpdate":"2024-07-16"},"enrollment":267,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Obesity"],"interventions":[{"type":"DRUG","name":"Tirzepatide","otherNames":["LY3298176"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"10 Milligrams (mg) Tirzepatide","type":"EXPERIMENTAL"},{"label":"15 mg Tirzepatide","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The main purpose of this study is to learn more about tirzepatide in participants with obesity disease. The study will also measure how Tirzepatide affects body weight with a low-calorie diet and increased physical activity. The study will last around 72 Weeks.","primaryOutcome":{"measure":"Mean Percent Change in Body Weight","timeFrame":"Baseline, 72 Weeks","effectByArm":[{"arm":"10 mg Tirzepatide","deltaMin":-17.8,"sd":0.94},{"arm":"15 mg Tirzepatide","deltaMin":-22.7,"sd":0.9},{"arm":"Placebo","deltaMin":-1.7,"sd":0.9}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.001"},{"comp":"OG001 vs OG002","p":"<0.001"}]},"eligibility":{"minAge":"20 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":12},"locations":{"siteCount":18,"countries":["Japan"]},"refs":{"pmids":["40031941"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":8,"n":73},"commonTop":["Covid-19","Constipation","Pyrexia","Nausea","Diarrhoea"]}}